BioCardia (NASDAQ:BCDA) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of BioCardia (NASDAQ:BCDA) in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a $25.00 target price on the stock.

BioCardia Stock Performance

Shares of BCDA opened at $1.85 on Thursday. The company’s 50-day simple moving average is $2.58 and its 200-day simple moving average is $3.31. BioCardia has a 1 year low of $1.84 and a 1 year high of $14.40. The stock has a market capitalization of $3.93 million, a PE ratio of -0.44 and a beta of 1.28.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.